Yoji Kishi
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Yoji Kishi is a Professor at the National Defense Medical College in Japan. His research areas encompass the evaluation of liver tumors through advanced imaging techniques, the prognosis of pancreatic and esophageal cancers, and the impacts of surgical treatments on postoperative outcomes. His recent publications include studies on the comparative effectiveness of imaging modalities in cancer diagnosis and the clinical implications of various prognostic factors in gastrointestinal cancers.
Recent Grants
Grant: Close
Invention of intraoperative image navigation system during hepatic resection
Open Date: 2011-01-01
Close Date: 2013-12-31
Articles (19)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Background Lymph node metastases beyond the hepatoduodenal ligament are sometimes encountered in locally limited T2 gallbladder cancer (GBCA). However, the incidence and impact on prognosis remain unclear. Methods This was a retrospective multi‐institutional study of patients who underwent surgical resection for GBCA from 2002 to 2022. The eighth edition of the Union for International Cancer Control staging was used for tumor‐node‐metastasis categorization. The lymph node location was classified as follows: (A) along the hepatoduodenal ligament and common hepatic artery; (B) posterior side of the pancreatic head; and (C) others. Metastasis to regions A, B, and C nodes was denoted as Na, Nb, and Nc, respectively. Results Data for 379 patients (pT1, 29; pT2, 162: pT3, 141; and pT4, 47) were evaluated; none with pT1 GBCA had node metastasis. For N1/2 GBCA, the proportion of patients with N2 disease increased with increasing T grade ( p = .001), while the proportions of patients with Na, Nb, and Nc disease were comparable between pT2 (61%, 26%, and 13%), pT3 (63%, 26%, and 12%), and pT4 (50%, 38%, and 12%) disease ( p = .681), respectively. Overall survival for pT2N1/2 disease (5 years, 43.8%) was comparable to that for pT3/4N0 disease (5 years, 37.2%; p = .192). Among patients with node‐positive pT2 disease, overall survival was comparable for Na, Nb, and Nc disease, with 5‐year survivals of 46%, 43%, and 31%, respectively ( p = .346). Conclusion Region B or C node metastasis was not rare even in pT2 GBCA. Regarding survival outcomes, pT2 node‐positive GBCA should be considered advanced disease irrespective of the extent of node metastasis.
Year:
2025
Carbohydrate restriction (ketogenic diet) is a cancer treatment that reduces energy production by oxidative phosphorylation in mitochondria of cancer cells and increases it through anaerobic glycolysis in cytoplasm. We report a patient in whom progression of pancreatic cancer recurrence was suppressed solely by a ketogenic diet for 9-month post-surgery. A 60-year-old female with a diagnosis of pancreatic cancer underwent pancreatoduodenectomy after 3 cycles of chemotherapy with gemcitabine plus nab-paclitaxel. Multiple pulmonary metastases were observed 22 months after the surgery. We administered gemcitabine plus nab-paclitaxel for 1 year. As the partial response continued for 1 year, we performed radiotherapy for the remnant pulmonary metastases followed by administration of S-1 for 6 months. Ten months after radiotherapy, CT showed exacerbation of the pulmonary metastases. As treatment, she requested severe carbohydrate restriction. After 9 months of the ketogenic diet, CT revealed stable disease. A ketogenic diet may have the therapeutic effect of suppressing tumor progression if strictly applied.
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (4)
Hiroshi Shinmoto
Professor
National Defense Medical College
Hironori Tsujimoto
-
Hideki Ueno
National Defense Medical College
Takehiro Noji
Professor
Hokkaido University
Make your next move.
Prepare your application
Review drafts before you send them.